Claims for Patent: 9,457,027

Summary for Patent: 9,457,027

Title:	Compounds for use in treatment of mucostis
Abstract:	The present invention provides methods for treating and/or preventing mucostitis with one or more compounds, or pharmaceutically acceptable salts thereof, disclosed herein, or compositions comprising the same.
Inventor(s):	Scott; Richard W. (Radnor, PA), Korczak; Bozena (Wayne, PA)
Assignee:	Cellceutix Corporation (Beverly, MA)
Application Number:	14/836,177
Patent Claims:	1. A method of treating mucositis in a mammal comprising administering to the mammal in need thereof a therapeutically effective amount of a compound having the formula ##STR00569## or a pharmaceutically acceptable salt thereof. 2. The method of claim 1 wherein the mammal is a human. 3. The method of claim 1 wherein the compound, or pharmaceutically acceptable salt thereof, administered to the mammal is present in a pharmaceutical composition. 4. The method of claim 3 wherein the pharmaceutical composition further comprises another therapeutic agent. 5. The method of claim 4 wherein the another therapeutic agent is palifermin. 6. The method of claim 1 wherein the mammal also receives chemotherapy, radiation therapy, or both. 7. The method of claim 1 wherein the compound is administered orally, bucally, or sublingually. 8. The method of claim 3 wherein the pharmaceutical composition is a liquid. 9. The method of claim 3 wherein the pharmaceutical composition is a rinse. 10. The method of claim 9 wherein the compound in the rinse is at 1 mg/ml, 3 mg/ml, or 10 mg/ml. 11. The method of claim 1 wherein the mammal also receives high-dose chemotherapy prior to hematopoietic cell transplantation, radiation therapy for tumors of the head and neck, induction therapy for leukemia, or conditioning regimens for bone marrow transplant. 12. A method of treating mucositis in a human comprising administering orally, bucally, or sublingually to the human in need thereof a liquid pharmaceutical composition in the form of a rinse comprising a compound having the formula ##STR00570## or a pharmaceutically acceptable salt thereof. 13. The method of claim 12 wherein the compound in the rinse is at 1 mg/ml, 3 mg/ml, or 10 mg/ml. 14. The method of claim 12 wherein the rinse further comprises palifermin. 15. A composition comprising ##STR00571## or a pharmaceutically acceptable salt thereof, and palifermin.

Details for Patent 9,457,027

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Swedish Orphan Biovitrum Ab (publ)	KEPIVANCE	palifermin	For Injection	125103	12/15/2004		2031-05-16